financetom
Business
financetom
/
Business
/
Authors sue Anthropic for copyright infringement over AI training
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Authors sue Anthropic for copyright infringement over AI training
Aug 20, 2024 7:49 AM

Aug 20 (Reuters) - Artificial intelligence company

Anthropic has been hit with a class-action lawsuit in California

federal court by three authors who say it misused their books

and hundreds of thousands of others to train its AI-powered

chatbot Claude.

The complaint, filed on Monday by writers and journalists

Andrea Bartz, Charles Graeber and Kirk Wallace Johnson, said

that Anthropic used pirated versions of their works and others

to teach Claude to respond to human prompts.

Anthropic did not immediately respond to a request for

comment on Tuesday. An attorney for the authors declined to

comment.

The lawsuit joins several other high-stakes complaints filed

by copyright holders including visual artists, news outlets and

record labels over the material used by tech companies to train

their generative artificial intelligence systems.

Separate groups of authors have sued OpenAI and Meta

Platforms ( META ) over the companies' alleged misuse of their

work to train the large-language models underlying their

chatbots.

The case filed Monday is the second against Anthropic

following a lawsuit brought by music publishers last year over

its alleged misuse of copyrighted song lyrics to train Claude.

The authors said in their complaint that Anthropic has

"built a multibillion-dollar business by stealing hundreds of

thousands of copyrighted books." Anthropic has drawn financial

backing from sources including Amazon ( AMZN ), Google

and former cryptocurrency billionaire Sam Bankman-Fried.

According to the complaint, the authors' works were included

in a dataset of pirated books that Anthropic used to train

Claude.

The lawsuit requested an unspecified amount of monetary

damages and an order permanently blocking Anthropic from

misusing the authors' work.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved